Eli Lilly Bets Big on Weight-Loss Pill With $550 Million Inventory Stockpile
(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing showed on Wednesday.
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly has said it is seeking permission to build ... be more than €400 million ($445 million), and could create 300 jobs at the plant itself, with another 500 positions required while ...
Hosted on MSN16d
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds ExpectationsGlobal pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint came in 1 ...
Learn More » For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45 ...
we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long-term growth stocks to buy right now. Released on Friday, February 7, the January jobs report ...
The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback